RxDoctor Payments Data

Robert Lewis, MD

Colon & Rectal Surgery · Bloomfield, CTNPI 1124175070

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (32.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 70.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $2,702, more than ten times the $206 reported in 2019.

$3,947in general payments, 2019–2025

Across 62 payments — averaging $63.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Johnson & Johnson$240
  • AbbVie$225
  • Takeda Pharmaceuticals U.S.A., Inc.$139
  • Fujifilm Healthcare Americas Corporation$119
  • Covidien LP$100
  • plus $351 from 12 others

What the payments were for

  • Speaking & faculty fees$40010%
  • Travel & lodging$1,29633%
  • Food & beverage$1,25032%
  • Education$1,00025%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,947 in reported general payments places this provider in the 70th percentile of 48 colon & rectal surgery providers in Connecticut.

See all colon & rectal surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$79,559
Medicare patients
160
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide14$663,238
LinzessLinaclotide11$10,136
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates103$6,089
ClenpiqSod Picosulf/Mag Ox/Citric Ac34$5,984
LoperamideLoperamide Hcl12$362
Neomycin Sulfate72$337
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$185
Metronidazole76$107
Ondansetron OdtOndansetron11$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$139$663,23814 claims
AbbVieLinzess$225$10,13611 claims
Ferring Pharmaceuticals Inc.Clenpiq$21$5,98434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 colon & rectal surgery providers in Connecticut.

Other colon & rectal surgery in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →